Alternative nucleic acid molecules containing reduced uracil content and uses thereof

Patent metadata

Field	Value
Publication number	US-10072057-B2
Application number	US-201715656740-A
Country	US
Kind code	B2
Filing date	Jul 21, 2017
Priority date	Nov 10, 2014
Publication date	Sep 11, 2018
Grant date	Sep 11, 2018

Abstract

The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising an mRNA encoding a polypeptide, and a pharmaceutically acceptable excipient, wherein the mRNA comprises:
(i) a 5′-cap structure;
(ii) a 5′-UTR;
(iii) an open reading frame (ORF) encoding the polypeptide,
wherein at least 95% of uracils in the ORF are 5-methoxyuracils; and
wherein the uracil content in the ORF is between the theoretical minimum and 150% of the theoretical minimum,

(iv) a 3′-UTR; and
(v) a poly-A region;
wherein the level of expression in a mammalian cell of the encoded polypeptide from the mRNA is increased relative to a reference mRNA comprising a reference open reading frame (rORF) encoding the polypeptide, wherein at least 95% of uracils in the rORF are 5-methoxyuracils, and wherein the uracil content in the rORF is from about 190% to about 200% of the theoretical minimum.

2. The pharmaceutical composition of claim 1 , wherein the uracil content in the ORF is between the theoretical minimum and 125% of the theoretical minimum.

3. The pharmaceutical composition of claim 1 , wherein the guanine content of the ORF is maximized for at least 50% of the codons, and wherein the ORF comprises at least one low frequency guanine maximized codon.

4. The pharmaceutical composition of claim 1 , wherein the cytosine content of the ORF is maximized for at least 50% of the codons, and wherein the ORF comprises at least one low frequency cytosine maximized codon.

5. The pharmaceutical composition of claim 1 , wherein the guanine and cytosine content of the ORF is maximized for at least 50% of the codons, and wherein the ORF comprises at least one low frequency guanine and cytosine maximized codon.

6. The pharmaceutical composition of claim 1 , wherein the uracil content is less than 20% of the total nucleobase content in the ORF.

7. The pharmaceutical composition of claim 1 , wherein the uracil content within any 20 nucleobase window within the ORF does not exceed 50%.

8. The pharmaceutical composition of claim 1 , wherein the 5′-cap structure is cap0, cap1, or ARCA inosine, N1-methyl-guanosine, 2′-fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, or 2-azido-guanosine.

9. The pharmaceutical composition of claim 1 , wherein the 3′-UTR is an alpha-globin 3′-UTR.

10. The pharmaceutical composition of claim 1 , wherein the poly-A region is between 80 to 120 nucleotides in length.

11. The pharmaceutical composition of claim 1 , wherein, upon contacting a mammalian cell, the mRNA has a longer half-life, greater area under the curve of protein expression, or both, relative to a corresponding wild-type mRNA.

12. The pharmaceutical composition of claim 1 , wherein the ORF further comprises at least one low-frequency codon.

13. The pharmaceutical composition of claim 1 , wherein the 3′-UTR of the mRNA comprises at least one microRNA (miRNA) binding site.

14. The pharmaceutical composition of claim 13 , wherein the miRNA is known to be expressed in liver cells or in immune cells.

15. The pharmaceutical composition of claim 14 , wherein the miRNA is chosen from miR-142-5p, miR-146-5p, or miR-146-3p.

16. The pharmaceutical composition of claim 14 , wherein the miRNA is miR-142-3p.

17. The pharmaceutical composition of claim 13 , wherein the miRNA is known to be expressed in liver cells, and is miR-122-5p or miR-122-3p.

18. The pharmaceutical composition of claim 1 , wherein the composition is in a single-unit dosage form.

19. The pharmaceutical composition of claim 1 , wherein the composition is in a multi-unit dosage form.

20. The pharmaceutical composition of claim 1 , wherein the mRNA is purified.

21. The pharmaceutical composition of claim 20 , wherein the mRNA is purified without reverse phase chromatography.

Assignees

• Modernatx Inc

Inventors

• Hoge Stephen G
• Issa William Joseph
• Miracco Edward John
• Nelson Jennifer
• Reynders John
• Stanton Matthew

Classifications

• A61K48/005

  characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered · CPC title

• C12N9/0069

  acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13) · CPC title

• C12Y113/12007

  Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase · CPC title

• C07K14/505

  Erythropoietin [EPO] · CPC title

• C12P21/02

  having a known sequence of two or more amino acids, e.g. glutathione · CPC title